Matches in SemOpenAlex for { <https://semopenalex.org/work/W36699577> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W36699577 endingPage "168" @default.
- W36699577 startingPage "153" @default.
- W36699577 abstract "Prostate carcinoma (PC) is the most common malign neoplasm found in men over 65 years of age. In Italy, the incidence of this cancer is around 60/100,000/year, corresponding to about 11,000 new cases each year. Patients with PC consume health resources for a cost that is 10-24% higher than that of similar populations without PC. It is estimated that in Italy, each year, there are 19,000 hospitalizations for prostate cancer in patients over 65, a figure that represents 4% of the total hospitalizations for oncological diseases. We conducted a marginal cost/effectiveness analysis of bicalutamide vs. flutamide, both administered in combination with LHRH, in patients with advanced (metastatic) PC, on the basis of a randomized trial comparing 4 strategies of total androgenic blockade (TAB). The analysis was conducted in the perspective of the SSN (National health system). The comparison revealed that drug acquisition costs are not the only determinants of the economical differences between the two therapeutical strategies. Furthermore, we demonstrated that prolonged survival of the patients does not increase the consumption of health resources, since the chronological shift of the terminal phase reduces the value of the resources dedicated to it. When conducing the cost/effectiveness analysis, the survival advantage associated to bicalutamide has been adjusted to balance the low quality of life of PC patients. The pharmacoeconomical benefit of bicalutamide resulted of 12,150 Euro/QALY, while the cost per year of life saved resulted inferior, ranging from 8.327 to 11.440 Euro. This cost/QALY value is nevertheless lower than that associated to several therapeutical strategies that are commonly accepted in developed countries (domiciliar hemodialysis, heart transplantation, breast cancer screening, etc.). Considering that 12.150 Euro/QALY is the highest estimate of the relative cost/effectiveness of bicalutamide, it appears that the combination bicalutamide + LHRH represents an economically acceptable alternative to flutamide + LHRH in advanced PC patients." @default.
- W36699577 created "2016-06-24" @default.
- W36699577 creator A5020186310 @default.
- W36699577 creator A5079400134 @default.
- W36699577 date "2003-09-15" @default.
- W36699577 modified "2023-09-25" @default.
- W36699577 title "Considerazioni cliniche ed economiche nel trattamento del cancro della prostata: analisi costo-efficacia di bicalutamide vs flutamide in combinazione con LHRH" @default.
- W36699577 doi "https://doi.org/10.7175/fe.v4i3.776" @default.
- W36699577 hasPublicationYear "2003" @default.
- W36699577 type Work @default.
- W36699577 sameAs 36699577 @default.
- W36699577 citedByCount "0" @default.
- W36699577 crossrefType "journal-article" @default.
- W36699577 hasAuthorship W36699577A5020186310 @default.
- W36699577 hasAuthorship W36699577A5079400134 @default.
- W36699577 hasBestOaLocation W366995771 @default.
- W36699577 hasConcept C121608353 @default.
- W36699577 hasConcept C126322002 @default.
- W36699577 hasConcept C126894567 @default.
- W36699577 hasConcept C143998085 @default.
- W36699577 hasConcept C2778313021 @default.
- W36699577 hasConcept C2780192828 @default.
- W36699577 hasConcept C2780962315 @default.
- W36699577 hasConcept C61367390 @default.
- W36699577 hasConcept C71924100 @default.
- W36699577 hasConceptScore W36699577C121608353 @default.
- W36699577 hasConceptScore W36699577C126322002 @default.
- W36699577 hasConceptScore W36699577C126894567 @default.
- W36699577 hasConceptScore W36699577C143998085 @default.
- W36699577 hasConceptScore W36699577C2778313021 @default.
- W36699577 hasConceptScore W36699577C2780192828 @default.
- W36699577 hasConceptScore W36699577C2780962315 @default.
- W36699577 hasConceptScore W36699577C61367390 @default.
- W36699577 hasConceptScore W36699577C71924100 @default.
- W36699577 hasIssue "3" @default.
- W36699577 hasLocation W366995771 @default.
- W36699577 hasOpenAccess W36699577 @default.
- W36699577 hasPrimaryLocation W366995771 @default.
- W36699577 hasRelatedWork W2067438553 @default.
- W36699577 hasRelatedWork W2092563355 @default.
- W36699577 hasRelatedWork W2093549003 @default.
- W36699577 hasRelatedWork W2127440557 @default.
- W36699577 hasRelatedWork W2376527279 @default.
- W36699577 hasRelatedWork W2461999566 @default.
- W36699577 hasRelatedWork W2600921168 @default.
- W36699577 hasRelatedWork W2758209720 @default.
- W36699577 hasRelatedWork W4245382454 @default.
- W36699577 hasRelatedWork W70951107 @default.
- W36699577 hasVolume "4" @default.
- W36699577 isParatext "false" @default.
- W36699577 isRetracted "false" @default.
- W36699577 magId "36699577" @default.
- W36699577 workType "article" @default.